This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: F20.8 (other schizophrenia) | Special Copayment Reduction: V161 (severe intractable disease, copayment reduced for 5 years after registration) |
| B. Synonyms | Other schizophrenia, cenesthopathic schizophrenia, schizophreniform disorder NOS, schizophreniform psychosis NOS |
| C. Adult onset | Likelihood of first onset in adulthood: possible - the subtypes included in F20.8 other schizophrenia vary in age of onset, and cenesthopathic schizophrenia mainly arises in adulthood (20s-40s). Schizophreniform psychosis NOS is used when the diagnostic duration criterion is not met at the stage of a first-episode psychosis. |
| 1. History | Cenesthopathic schizophrenia: Huber's description of cenesthopathic schizophrenia (1957) → recognized as an independent clinical entity in German-speaking regions → included in ICD-10 F20.8; schizophreniform disorder: Langfeldt's schizophreniform psychosis (1937) → changes in the DSM classification. |
| 2. Causes | Cenesthopathic subtype: parietal lobe and insular cortex abnormalities involved in abnormal bodily perception; common etiology of schizophrenia overall + abnormal somatosensory processing; schizophreniform psychosis: early stage of schizophrenia or a transitional stage before the typical course. |
| 3. Genetics | Genetic predisposition common to schizophrenia; genetic factors related to somatosensory body self-representation, involved in the features of cenesthopathy, are under study. |
| 4. General epidemiology | F20.8 includes heterogeneous subgroups, making a single prevalence statistic difficult; cenesthopathic schizophrenia: estimated at about 3-5% of schizophrenia; schizophreniform psychosis: about 1-2 times the incidence of schizophrenia. |
| 5. Pathophysiology | Cenesthopathy: abnormal parietal somatosensory integration, insular cortex bodily self-awareness, and prefrontal regulation of body representation; specific abnormalities of bodily perception processing added to the mechanisms common to schizophrenia. |
| 6. Symptoms | Cenesthopathic schizophrenia: strange sensations inside the body (electric current flowing, something moving inside the body, a feeling of tissue change) together with psychotic symptoms; schizophreniform psychosis: typical schizophrenia symptoms lasting less than 6 months. |
| 7. Signs | Cenesthopathy: complaints describing body parts in a concrete and bizarre way; multiple physical examinations normal; on mental status examination, delusions related to bodily harm and abnormal bodily perception coexist. |
| 8. Screening | Cenesthopathy: psychiatric referral system for patients with somatic symptom complaints; systematic differentiation from somatoform disorder and somatic symptom disorder; assessment of the PANSS somatic concern item. |
| 9. Diagnosis | ICD-10 F20.8: cases meeting schizophrenia criteria not included in F20.0-F20.6; in cenesthopathic schizophrenia, abnormal bodily perception dominates the clinical picture; exclusion of organic, somatoform, and medical conditions is essential. |
| 10. Treatment | Second-generation antipsychotics; CBT targeting abnormal bodily perception in cenesthopathy; supportive psychotherapy for preoccupation with somatic symptoms; treatment of comorbid depression and anxiety. |
| 11. Prognosis | Schizophreniform psychosis: high recovery rate, remission possible without relapse; cenesthopathic schizophrenia: abnormal bodily perception tends to become chronic; overall prognosis varies with the specific clinical presentation. |
| 12. Prevention | Early psychosis intervention; early recognition of cenesthopathy symptoms and facilitating psychiatric referral; maintenance therapy for relapse prevention; systematic psychiatric linkage for patients with a somatization tendency. |
| 13. References | Huber G. Cenesthopathic schizophrenia — clinical and genetic aspects. Fortschr Neurol Psychiatr. 1983 … and 9 other papers |
F20.8 "other schizophrenia" is a "residual category" in the ICD-10 classification that accommodates cases meeting schizophrenia criteria not included in F20.0-F20.6. The clinical history of this category is understood mainly as the history of two subtypes: cenesthopathic schizophrenia and schizophreniform psychosis.
Cenesthopathic schizophrenia: This distinctive subtype was first systematically described in 1957 by the German psychiatrist Gerd Huber. Huber described a group of schizophrenia patients who mainly complained of strange sensations inside the body - a feeling of electric current flowing, something moving or twisting in a particular body part, a feeling of tissue changing, strange changes in body boundaries - and named it "cenesthopathic schizophrenia (Zönästhopathische Schizophrenie)." "Cenesthopathy (or cenesthesia)" refers to strange and unpleasant sensations arising inside the body, derived from the Greek koinos (common) and aisthesis (sensation).
Huber referred to cases in which these symptoms may appear in the early or residual stage of schizophrenia and abnormal bodily perception dominates the clinical picture over typical paranoid symptoms or thought disorder. This concept was widely accepted in German-language psychiatry but is relatively less known in the English-speaking world. ICD-10 included this subtype in F20.8.
Schizophreniform psychosis/disorder: The Norwegian psychiatrist Gabriel Langfeldt proposed the concept of "schizophreniform psychoses" in 1937. He sought to distinguish schizophrenia-like symptom states that do not show the typical schizophrenia course (poor prognosis) and from which full recovery is possible. This concept was later modified in the DSM classification, and DSM-III included "schizophreniform disorder" as an independent diagnosis for schizophrenia-like symptom states lasting less than 6 months. ICD-10 F20.8 includes "schizophreniform psychosis NOS," which does not meet the duration criterion or does not fall under a specific subtype. While ICD-10 does not require the 6-month duration criterion for a diagnosis of F20 schizophrenia, DSM-5 retains the 6-month criterion, so there is a systematic difference.
The causes of F20.8 other schizophrenia differ somewhat depending on the subtype included, and the vulnerability-stress model of schizophrenia in general is the common basis.
Specific causal factors of cenesthopathic schizophrenia: In cenesthopathic schizophrenia, in which abnormal internal bodily perception is prominent, abnormal processing of body self-representation in the parietal lobe (especially the posterior parietal cortex) and insula is proposed as the core cause. Normal body self-representation depends on multisensory integration of proprioception, interoception, and touch, and abnormalities in this integration underlie the bizarre sensations arising inside the body. The insula is a key structure for interoceptive processing, and studies link insular dysfunction to cenesthopathic experiences.
Causal factors common to schizophrenia: Dopamine system abnormalities, NMDA receptor hypofunction, and GABA interneuron abnormalities are common causes of schizophrenia in general and also apply to F20.8. In cenesthopathic schizophrenia, these common mechanisms interact with abnormal bodily perception processing to produce the distinctive clinical presentation.
Causes of schizophreniform psychosis: Schizophreniform psychosis has the same etiologic factors as schizophrenia, but differences in onset course, likelihood of stress precipitation, or genetic burden produce differences in prognosis. Precipitating factors such as acute stressful events, substance use, and sleep deprivation may play a larger role in triggering schizophreniform psychosis.
The genetics of F20.8 other schizophrenia share the polygenic risk architecture of schizophrenia in general, and research on subtype-specific genetic factors is very limited.
Genetic predisposition common to schizophrenia: The 287 schizophrenia risk loci identified in the PGC GWAS also apply to F20.8. There is indirect evidence that polygenic risk scores (PRS) in cenesthopathic schizophrenia and schizophreniform psychosis show a distribution similar to that of typical schizophrenia.
Genes related to somatosensory processing: Genes associated with parietal lobe function involved in body self-representation processing (synaptic adhesion and organization genes such as PCDH19 and the SHANK gene family) may contribute to the abnormal bodily perception of cenesthopathic schizophrenia, but direct evidence is lacking.
Genetic characteristics of schizophreniform psychosis: Family studies report a high proportion of schizophrenia among relatives of patients with schizophreniform psychosis, but the proportion of relatives with mood disorders is also elevated. This suggests that schizophreniform psychosis may lie at a point of genetic overlap between schizophrenia and mood disorders. Among patients with DSM-5 schizophreniform disorder, the diagnosis of some changes to bipolar disorder over the long-term course, and this genetic overlap explains the change.
F20.8 other schizophrenia is a category that includes heterogeneous subgroups, so it is difficult to describe with a single prevalence statistic. Understanding the epidemiologic characteristics of each subtype is clinically more useful.
Prevalence of cenesthopathic schizophrenia: Cenesthopathic schizophrenia is rarely diagnosed in Western psychiatry, but it is reported to account for about 3-5% of schizophrenia in German-speaking countries. Abnormal bodily perception is quite common in schizophrenia patients, but only cases in which it dominates the clinical picture are diagnosed as cenesthopathic schizophrenia, so the prevalence is reported as low. Delayed diagnosis is common, as patients go from department to department (internal medicine, neurology, dermatology, orthopedics, etc.) with complaints of abnormal sensations in various body parts before finally being referred to psychiatry.
Prevalence of schizophreniform psychosis NOS: The prevalence of schizophreniform disorder (DSM criteria) is reported as about 1-2 times that of schizophrenia. However, many cases convert to schizophrenia or mood disorder during the course. A high proportion of first-episode psychosis cases receive a schizophreniform diagnosis for not meeting the 6-month duration criterion, and about 30-50% of these meet the diagnostic criteria for schizophrenia within 1-2 years.
Age of onset and sex: Cenesthopathic schizophrenia tends to arise in adulthood (mainly 20s-40s), with no specific sex difference. Schizophreniform psychosis shows an age-of-onset distribution similar to schizophrenia but tends to have a better prognosis.
The pathophysiology of F20.8 other schizophrenia differs depending on the subtype included, and here the mechanisms of cenesthopathic schizophrenia and schizophreniform psychosis are mainly described.
Pathophysiology of cenesthopathic schizophrenia: The insular cortex is a key structure for interoception, that is, awareness of the internal state of the body. Normal insular function integrates internal and external bodily sensations and forms body self-representation, and abnormalities of this function underlie cenesthopathic experiences (strange sensations inside the body). Abnormal multisensory integration in the parietal lobe (especially the inferior parietal lobule and somatosensory cortex) also causes confusion in body boundaries and proprioceptive processing. The dopamine and glutamate abnormalities common to schizophrenia are added to this abnormal bodily perception, so that bizarre bodily experiences are interpreted delusionally and systematized.
Pathophysiology of schizophreniform psychosis: Schizophreniform psychosis shares the same neurobiological mechanisms as typical schizophrenia (dopamine overactivity, NMDA hypofunction), but is understood to have a more acute onset course, with precipitating factors (extreme stress, sleep deprivation, substance use) playing a larger role. In some cases the genetic burden is relatively low and environmental stress accounts for a larger share, which is explained as allowing complete remission after the precipitating factor disappears.
The clinical symptoms of F20.8 other schizophrenia vary depending on the subtype included.
Symptoms of cenesthopathic schizophrenia: The core symptom is strange and unpleasant sensations arising inside the body. Patients describe these sensations in a very concrete and vivid way: "electricity is flowing in my brain," "something is moving in my spine," "my stomach feels like it is turning over," "bugs are crawling under my skin," "my heart feels different," "the size of my body parts seems to change," and so on. These sensations are very real to the patient, and because no abnormality is found on objective physical examination, patients go from department to department for a long time. In addition to cenesthopathic symptoms, other symptoms of schizophrenia (delusions, auditory hallucinations, negative symptoms) may accompany.
Symptoms of schizophreniform psychosis NOS: Typical schizophrenia symptoms (delusions, auditory hallucinations, disorganized thinking, negative symptoms) appear, but the 6-month duration criterion is not met or the case does not fall under a specific subtype. The qualitative character of symptoms is similar to typical schizophrenia, but onset may be more acute and the course shorter.
Common schizophrenia symptoms: Along with the specific symptoms above, the general symptoms of schizophrenia such as delusions, hallucinations, thought disorder, and negative symptoms accompany. The F20.8 code is used when these meet the diagnostic criteria for schizophrenia but do not fully fall under any subtype of F20.0-F20.6.
The clinical signs of F20.8 other schizophrenia vary by subtype, but the distinctive signs of cenesthopathic schizophrenia are clinically the most important.
Distinctive signs of cenesthopathic schizophrenia: Patients describe bodily symptoms in great detail and in a peculiar way, are not convinced by medical test results, or feel that the results do not match their subjective experience. They may repeatedly request examination of body parts, or record and present particular sensations. The content of the bodily symptom complaints has a bizarre character that is difficult to explain anatomically or physiologically. In some cases the accompanying delusional content forms in the direction of explaining the abnormal bodily perception (e.g., "I am being experimented on with medical devices," "a foreign object has been inserted into my body").
History of going from department to department: A history of having been examined in various departments such as neurology, internal medicine, orthopedics, dermatology, and otolaryngology without abnormal findings is a diagnostic clue. The combination of the distinctive qualitative character of cenesthopathic symptoms and this history suggests cenesthopathic schizophrenia.
Mental status examination: Conviction about abnormal bodily perception (varying with the degree of delusional conviction), the emotional response to it (anxiety, distress), and delusional thinking related to the body are observed. The overall mental status examination also assesses the other symptoms of schizophrenia.
In screening for F20.8 other schizophrenia, especially cenesthopathic schizophrenia, the key is the clinical competence to consider a psychiatric cause in patients who mainly complain of bodily symptoms.
Screening for cenesthopathic schizophrenia - referral system for somatic symptoms: A system for early psychiatric referral of patients who complain of repeated, unexplained bodily symptoms (bizarre or strange sensations inside the body) in internal medicine, neurology, and other clinical departments is important. When "medically unexplained symptoms" are present, especially when their content is anatomically bizarre or atypical, the possibility of the schizophrenia spectrum should be considered.
Assessment of the PANSS somatic concern item: Item G13 (somatic concern) of the PANSS general psychopathology subscale is useful for assessing somatic delusions and cenesthopathic symptoms. This item is assessed systematically in schizophrenia patients with bodily symptom complaints.
Screening for schizophreniform psychosis: The possibility of schizophreniform psychosis is assessed in first-episode psychosis cases that do not meet the diagnostic duration criterion (ICD-10: 1 month; DSM-5 schizophrenia: 6 months). The SIPS and CAARMS are used to track symptom severity and duration.
Diagnosis of F20.8 other schizophrenia is the process of confirming that the general criteria for schizophrenia are met while the criteria for the specific subtypes of F20.0-F20.6 are not.
Conditions for applying ICD-10 F20.8: ① The general criteria for schizophrenia (F20) must be met. ② The criteria for F20.0 (paranoid), F20.1 (hebephrenic), F20.2 (catatonic), F20.3 (undifferentiated), F20.4 (post-schizophrenic depression), F20.5 (residual), and F20.6 (simple) are not met. ③ When other specified schizophrenia features (cenesthopathy, schizophreniform psychosis) are present in the clinical picture, code as F20.8.
Diagnostic points of cenesthopathic schizophrenia: The diagnostic core is meeting the general criteria for schizophrenia + abnormal internal bodily sensation (cenesthopathy) as the main feature of the clinical picture + exclusion of physical illness that explains the bodily symptoms (physical examination, imaging, blood tests). Differential diagnosis: ① somatic symptom disorder: no psychotic symptoms. ② paranoid disorder with somatic delusions: does not meet the general criteria for schizophrenia. ③ neurological causes (multiple sclerosis, etc.): abnormal findings on MRI.
Diagnosis of schizophreniform psychosis: When typical schizophrenia symptoms are present but the duration criterion is not met (in ICD-10, not meeting 1 month, or for another specific reason), or when there is a distinctive clinical presentation, consider applying the F20.8 or F23 (acute and transient psychotic disorders) category.
Treatment of F20.8 other schizophrenia follows the standard treatment principles for schizophrenia in general, but an approach that takes the characteristics of the subtype into account is needed.
Antipsychotics: Second-generation antipsychotics are first-line treatment. There are reports that abnormal bodily perception in cenesthopathic schizophrenia is partially improved by antipsychotics, but the effect is limited in some cases. Clozapine is considered in cenesthopathic schizophrenia that does not respond to other drugs. In schizophreniform psychosis, when symptoms resolve quickly after acute-phase treatment, determining the duration of maintenance therapy is important.
Psychotherapy for cenesthopathic symptoms: CBT for abnormal bodily perception can be helpful. Cognitive restructuring that challenges delusional interpretation of bodily sensations and mindfulness-based approaches to reduce preoccupation with the body are used adjunctively. Supportive psychotherapy relieves distress caused by bodily symptoms and strengthens the therapeutic alliance.
Multidisciplinary collaboration: Because patients with cenesthopathic schizophrenia often go from department to department, close collaboration between the treating psychiatrist and physicians in other clinical departments is important to reduce unnecessary tests and procedures. Diagnostic education helps patients and families understand the psychiatric basis of the bodily symptoms.
Treatment of comorbid symptoms: Depression and anxiety often accompany, and an appropriate antidepressant or anxiolytic is added. Ongoing management is needed for sleep disturbance and decline in social functioning due to preoccupation with bodily symptoms.
The prognosis of F20.8 other schizophrenia differs greatly depending on the subtype included.
Prognosis of cenesthopathic schizophrenia: Abnormal bodily perception tends to become chronic, and a chronic course with repeated improvement and worsening, rather than complete symptom resolution, is common. Partial improvement is possible with antipsychotic treatment, but the cenesthopathic symptoms themselves may be treatment-resistant in some cases. The longer the diagnostic delay, the more fixed the preoccupation with bodily symptoms becomes and the lower the treatment response, so early psychiatric referral is important.
Prognosis of schizophreniform psychosis NOS: Schizophreniform psychosis is known to have a better prognosis than typical schizophrenia. Complete remission is achieved in about 30-50%, and some remain relapse-free. However, in about 50-70% the diagnosis changes to schizophrenia or schizoaffective disorder during the course, and in this case the prognosis becomes similar to schizophrenia in general. Early onset, insidious onset, predominant negative symptoms, and family history predict a poor prognosis.
Overall determinants of prognosis: For F20.8 as a whole, early diagnosis and initiation of appropriate treatment, family support, and a community-based treatment approach have a positive effect on prognosis. Quickly excluding organic causes and linking patients to appropriate treatment is key to improving prognosis.
Prevention of F20.8 other schizophrenia follows the prevention strategies for schizophrenia in general, and shortening the diagnostic delay of cenesthopathic schizophrenia is particularly important.
Shortening diagnostic delay in cenesthopathic schizophrenia: Improving non-psychiatrists' awareness of cenesthopathic schizophrenia is key. A systematic psychiatric referral pathway for "bizarre bodily sensations that are medically unexplained" needs to be established. Early psychiatric referral shortens diagnostic delay and allows intervention before preoccupation with bodily symptoms becomes fixed.
Early psychosis intervention: In first-episode psychosis, including schizophreniform psychosis, shortening DUP and early treatment intervention are decisive for long-term prognosis. Linkage to EIP (Early Intervention in Psychosis) programs is important.
Relapse prevention: Relapse is prevented with maintenance antipsychotic therapy after acute-phase treatment. In cenesthopathic schizophrenia, worsening of bodily symptoms may be a leading signal of a relapse of schizophrenia overall, so regular follow-up is necessary.
Strengthening psychiatric linkage for patients with a somatization tendency: Strengthen the pathway for systematically linking patients with repeated, unexplained bodily symptoms in primary care and non-psychiatric clinical departments to mental health services.
Huber G. Cenesthopathic schizophrenia — clinical and genetic aspects. Fortschr Neurol Psychiatr. 1983;51(3):66-82. PMID: 6343753.
Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. Lancet. 2022;399(10323):473-486. DOI: 10.1016/S0140-6736(21)01730-X. PMID: 35093236.
Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962. DOI: 10.1016/S0140-6736(13)60733-3. PMID: 23810019.
Strakowski SM. Schizophreniform disorder. In: Sadock BJ, Sadock VA, Ruiz P, eds. Kaplan and Sadock's Comprehensive Textbook of Psychiatry. 10th ed. Wolters Kluwer; 2017.
Trubetskoy V, Pardiñas AF, Qi T, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature. 2022;604(7906):502-508. DOI: 10.1038/s41586-022-04434-5. PMID: 35396580.
Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067. DOI: 10.1038/nrdp.2015.67. PMID: 27189524.
Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018;17(2):149-160. DOI: 10.1002/wps.20516. PMID: 29745131.
National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. NICE guideline CG178. 2014 (updated 2019). Available at: https://www.nice.org.uk/guidance/cg178.
Howes OD, Murray RM. Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet. 2014;383(9929):1677-1687. DOI: 10.1016/S0140-6736(13)62036-X. PMID: 24315522.
Park SC, Jang EY, Park YC. Prevalence, correlates, and impact of schizophrenia on daily life in Korea. Psychiatry Investig. 2018;15(6):580-586. DOI: 10.30773/pi.2017.11.16. PMID: 29961308.